Biosig Technologies (STEX) Stock Price, News & Analysis

Company Overview

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion. The technology is intended to integrate with existing electrophysiology lab equipment and workflows, supporting procedures such as ablations used to treat atrial fibrillation and other arrhythmias. By enhancing signal fidelity, the company aims to support procedural efficiency and clinical decision-making for electrophysiologists and hospital electrophysiology labs.

Biosig positions its product development around clinical validation and regulatory pathways common to medical device commercialization, and it targets adoption by hospitals, specialty clinics and physician groups that perform invasive cardiac electrophysiology procedures. The company pursues clinical studies and collaborations to demonstrate the clinical utility of its technology and to support broader commercialization within the medical community.

Key Stats

• Today's Range: $0.74 to $0.83
• 50-Day Range: $0.69 to $1.09
• 52-Week Range: $0.66 to $7.44
• Volume: 672,247 shs
• Average Volume: 932,070 shs
• Market Capitalization: $89.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Biosig Technologies Stock Analysis - MarketRank™

Biosig Technologies scored higher than 73% of companies evaluated by MarketBeat, and ranked 459th out of 851 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Biosig Technologies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Biosig Technologies has a consensus price target of $4.00, representing about 418.3% upside from its current price of $0.77.

Amount of Analyst Coverage

Biosig Technologies has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Biosig Technologies is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biosig Technologies is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biosig Technologies has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.43% of the float of Biosig Technologies has been sold short.

Short Interest Ratio / Days to Cover

Biosig Technologies has a short interest ratio ("days to cover") of 9.26.

Change versus previous month

Short interest in Biosig Technologies has recently decreased by 13.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biosig Technologies does not currently pay a dividend.

Dividend Growth

Biosig Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: N/A

News Sentiment

Biosig Technologies has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Finance companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Biosig Technologies this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for STEX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added Biosig Technologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $24,500.00 in company stock, which represents 0.0273% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Biosig Technologies insiders have bought 98.00% more of their company's stock than they have sold. Specifically, they have bought $49,500.00 in company stock and sold $25,000.00 in company stock.

Percentage Held by Insiders

52.73% of the stock of Biosig Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

7.16% of the stock of Biosig Technologies is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 8/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Finance
• Industry: Capital Markets
• Sub-Industry: Asset Management & Custody Banks
• Current Symbol: NASDAQ:STEX
• CIK: 1530766
• Web: biosig.com
• Phone: (203) 409-5444
• Fax: N/A
• Employees: 50
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Biosig Technologies: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +418.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$462.77 million
• Net Margins: N/A
• Pretax Margin: -344,630.84%
• Return on Equity: -462.48%
• Return on Assets: -307.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.20
• Quick Ratio: 20.21

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 2,247.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.26 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 116,460,000
• Free Float: 55,053,000
• Market Cap: $89.88 million
• Optionable: N/A
• Beta: 1.98